People

MapLight Therapeutics clinical adviser and Banner Alzheimer’s Institute director. Researches dementia care, prevention and treatment trials, biomarkers and neuropsychiatric symptoms. Trained in medicine at Rochester and previously worked at NIMH and Rochester.

MapLight Therapeutics clinical adviser and biotechnology clinical development consultant. Former Alkermes medical and clinical leader and Northwestern pediatric endocrinologist. Studied biophysics at Pennsylvania and medicine at Mount Sinai.

MapLight Therapeutics clinical adviser and director of the University of Rochester AD-CARE program. Researches memory disorders, Alzheimer’s disease clinical trials, biomarkers and behavioral symptoms. Holds a medical degree from the University of Iceland.

MapLight Therapeutics clinical adviser and CognitionMetrics president. Neuropsychologist advising CNS clinical programs on cognition and psychometrics; previously worked at Cogstate and AstraZeneca. Holds a Yeshiva doctorate and a John Jay public administration degree.

MapLight Therapeutics clinical adviser and Hofstra/Northwell psychiatry professor studying schizophrenia treatment and recovery. Previously chaired psychiatry at Zucker Hillside Hospital and the Zucker School of Medicine. Earned a medical degree at NYU.

Clinical advisory board member of ProMIS Neurosciences and MapLight Therapeutics, and founder and chief executive of Pentara. Statistician specializing in Alzheimer’s disease and degenerative conditions, with a Boston University doctorate.

MapLight Therapeutics clinical adviser and Stony Brook psychiatry chair. Researches dopamine transmission and brain imaging in schizophrenia and addiction, including PET methods. Holds a medical degree from St. Joseph University in Beirut and trained at Tennessee, NIMH and Yale.

MapLight Therapeutics scientific adviser and Stanford neurosurgery and neuroscience professor. Studies neuronal circuits, oscillations and epilepsy mechanisms. Earned a doctorate at Eötvös University and previously led a laboratory and department at UC Irvine.

MapLight Therapeutics scientific adviser and Allen Institute for Brain Science executive vice president and director. Leads research on brain cell types and connectivity atlases. Holds a Brandeis molecular and cell biology doctorate and completed postdoctoral research at MIT.

MapLight Therapeutics scientific adviser and UCSF psychiatrist and geneticist studying neurodevelopmental disorders. His research uses genetic discoveries to investigate autism and related syndromes. Trained in medicine at Stanford and genetics at Yale; previously held a Yale faculty position.

MapLight Therapeutics director with finance and investment operating experience. Former founding partner and chief financial officer of Patient Square Capital; earlier held senior roles at KPMG, Forward Ventures and Lightspeed Venture Partners. Co-founded the now dormant Alzheimer’s startup Recuerdo Therapeutics.

Director at MapLight Therapeutics and Stellaromics and chief executive of a Silicon Valley single-family office. Has experience across investment management, public and private companies and nonprofit boards.

MapLight Therapeutics director and Forbion general partner focusing on clinical-stage biotechnology. Previously invested at Novo Holdings and Apposite Capital. Holds a UCL neuroscience doctorate, a Cambridge MBA and an Oxford undergraduate degree.

MapLight Therapeutics independent director. Previously spent more than two decades at Eli Lilly, including chief medical officer duties from 2008 to 2021, overseeing clinical development, medical affairs and regulatory work across several therapeutic areas.

MapLight Therapeutics director. Former Foundation Medicine chief executive and Genentech senior executive, with earlier CNS leadership experience at UCB. His MapLight biography also identifies him as board chair of SOPHiA GENETICS.

MapLight Therapeutics director and Alumis president, chief executive and board chair. Previously led Principia Biopharma through its acquisition by Sanofi and served as Talima Therapeutics chief executive and a Genentech commercial leader.

MapLight Therapeutics co-founder and scientific adviser. Stanford psychiatry professor and Wu Tsai Neurosciences Institute deputy director researching synaptic biology. Previously taught at UCSF. Holds Stanford medical and neuroscience doctoral degrees and an undergraduate degree from Harvard.

Stanford neuroscience professor and physician; scientific co-founder and adviser at Stellaromics and co-founder and scientific adviser at MapLight Therapeutics. Research developed optogenetics and STARmap-related spatial biology methods.

MapLight Therapeutics general counsel, also known formally as Kristopher L. Hanson. Previously led legal and compliance work at PhaseBio and Nalpropion and served in senior legal roles at Orexigen and other companies. Studied at Georgetown and UCLA School of Law.

MapLight Therapeutics interim chief financial officer and chief administrative and accounting officer. Previously led finance at OvaScience and worked in external reporting at GFI Software and audit at PwC. Holds undergraduate and graduate accounting degrees from Babson.

MapLight Therapeutics chief discovery officer, developing neural-circuit discovery methods. Previously a UCSF physiology and neurology professor researching basal ganglia function, Parkinson’s disease and dyskinesia. Studied at Berkeley and Harvard and trained at Stanford.

MapLight Therapeutics chief scientific officer, responsible for preclinical research. Former OvaScience scientific leader and Sanofi Genzyme vice president of in vitro biology; earlier worked at Millennium and Scriptgen. Holds a Harvard doctorate and a Wesleyan undergraduate degree.

MapLight Therapeutics chief medical officer and cognitive neurologist. Previously directed dementia and neurodegeneration clinical programs at Acadia Pharmaceuticals and conducted translational research at the University of Virginia. Holds a Baylor genetics doctorate and a Jefferson medical degree.

Head of the risk-management function published by Vertis. Junior Partner at Quantyx, responsible for venture-capital-fund risk management and risk advisory for Italian and European managers. Studied business economics at Bocconi; the functional Vertis appointment does not imply employment as a Vertis investment partner.

IAG publishes Luigi Capello as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: CEO di LVenture Group. Digital Deep Tech Imprenditore e Business Angel di successo, Luigi ha gestito importanti fondi di Private equity e nel 2007 ha cofondato IAG – Italian Angels for growth. Luigi è inoltre fondatore di Luiss Enlbas, acceleratore di startup digitali. Attualmente Luigi è CEO di LVenture Group, Fondo VC quotato in Borsa Italiana. Luigi è stato inoltre menzionato dalla community “Hot Topics” nella lista dei 100 leader più influenti di acceleratori di startup.

Raymond Yuan is a vice president at Pivotal Life Sciences and Nan Fung Group in Hong Kong. He joined the group in 2018 after work in McKinsey's chemicals and agriculture practice. He holds a chemical engineering master's degree from Imperial College London.

Allison Vuong is a senior software engineer at Pivotal Life Sciences, developing data infrastructure for its AI, machine learning and investment teams. Her earlier work included ImmuneBridge consulting, data integration platforms at Genentech and bioinformatics pipelines at Bayer CropScience. She holds a UC Berkeley bioengineering degree.

AJ Velasquez-Mao is a senior associate on Pivotal's San Francisco investment team, which he joined in 2026. He previously invested in early-stage therapeutics at Dolby Family Ventures and covered biotechnology at Jefferies. He holds a joint UC Berkeley/UCSF bioengineering PhD and an undergraduate bioengineering degree from Rice University.

Solo Wu is a vice president at Pivotal Life Sciences and Pivotal bioVenture Partners China. He joined the China operation in 2019 after management consulting in China and Singapore, including L.E.K. Consulting. He holds bachelor's and master's degrees in chemistry from the National University of Singapore.

Ashley Power is an executive assistant in Pivotal's San Francisco operation, which she joined in 2021. Her earlier executive support and operations roles included Bay City Capital and Climate Policy Initiative. She holds an environmental sustainability and social justice degree from San Francisco State University.

Lance Miles is a senior machine learning engineer at Pivotal Life Sciences. He develops production infrastructure and AI tools for biotechnology investment analysis, including applications of large language models. He holds a Master of Information and Data Science degree from UC Berkeley.

Brian Mills is a vice president on Pivotal's San Francisco investment team, which he joined in 2022. He previously covered biotechnology at Jefferies and researched translational biomarkers for neurological and psychiatric diseases as a Stanford postdoctoral scholar. He holds a neuroscience PhD from Oregon Health and Science University.

Ming Luo directs human resources for Pivotal Life Sciences and Pivotal bioVenture Partners China. She joined in 2021 after healthcare and life sciences executive search work at Heidrick & Struggles and other consulting firms. She holds a Washington University in St. Louis MBA and a finance degree from the Central University of Finance and Economics.

Han Li is a data scientist in Pivotal Life Sciences' Shanghai AI and Data Intelligence team. Her experience includes machine learning and statistical analysis in market research and online insurance. She holds a computational biology PhD and statistics master's degree from the University of Southern California, and a biology degree from the University of Science and Technology of China.

Jeni Lee is a partner with Pivotal bioVenture Partners in the US, which she joined in 2019. She invests in therapeutics and life sciences, with an early-stage therapeutics focus, following work at Novo Ventures and Aquilo Capital. She co-founded ViVita Technologies and holds a biomedical engineering PhD from UC Davis and a bioengineering degree from UC Berkeley. She is distinct from the Jennifer Lee records at Basis Set Ventures and Parallel Bio.

Felix Fu is vice president of research on Pivotal's Shanghai AI and Data Intelligence team. He previously worked in biotechnology competitive intelligence and business development, co-founded science communication agency Quisite Science, and worked in McKinsey's healthcare research practice. He holds a PhD in developmental genetics from New York University.

Charlotte Chow is an investment associate in Pivotal's Hong Kong team. She joined Nan Fung Group in 2022 after healthcare investment banking at Fosun Hani Securities. She holds a biomedical science degree from Imperial College London.

Lisa Cai is portfolio manager at Pivotal Life Sciences and a director in the Nan Fung Group CEO office. Her public-equity background includes healthcare investment research at NF Trinity, Agamemnon Capital and SAFE, following private-equity work at Morgan Stanley. She holds an MBA from Wharton and undergraduate degrees from UC Berkeley.

Emerald Bloom-Johnson manages HR and talent for Pivotal Life Sciences. She joined its San Francisco operation in 2019 and supports US human resources and Peter Bisgaard. Her earlier experience spans executive support, real estate investment management, entrepreneurship and events; she studied business marketing at California State University Monterey Bay.

Glenn Batchelder is a venture partner with Pivotal bioVenture Partners in the US. He co-founded and led Civitas Therapeutics and previously served as CEO of BIND Therapeutics and Acceleron Pharma. His biotechnology operating background includes Millennium Pharmaceuticals; he holds a chemical engineering degree from Lehigh University. Glenn Batchelder is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Mischa Travers is US chief operating officer and general counsel at Pivotal Life Sciences, which he joined in 2022. He previously served as CFO and general counsel of Cequence Security and as a partner at Davis Polk & Wardwell. He holds a JD from the University of Chicago and an industrial and systems engineering degree from Virginia Tech.

Anna Sun is China chief operating officer at Pivotal Life Sciences and a director in the Nan Fung Group CEO office. Before joining the group she worked in interest-rate structuring at Barclays Capital. She holds bachelor's and master's degrees in finance from Tsinghua University; Anna Xintong Sun is the name used in securities filings.

Tony Ho is senior science partner at Pivotal Life Sciences. A physician and biotechnology R&D executive, he previously led R&D at CRISPR Therapeutics, oncology integration and innovation at AstraZeneca, and neurology and ophthalmology at Merck. He co-founded Neuronyx and holds an electrical engineering degree from UCLA and an MD from Johns Hopkins. He is a different person from General Catalyst engineering partner Tony Ho.

Rob Hopfner is managing director of Pivotal Life Sciences and managing partner of Pivotal bioVenture Partners in the US. He joined in 2017 after investment leadership at Bay City Capital. His background includes pharmacy, a pharmacology doctorate from the University of Saskatchewan, an MBA from Chicago Booth and postdoctoral research at Harvard Medical School. Robert Hopfner is the name used in securities filings.

Vincent Cheung chairs Pivotal Life Sciences and is managing director and chief executive officer of Nan Fung Group. He founded the US Pivotal bioVenture Partners operation in 2017 and its China counterpart in 2018, and studied molecular and cell biology at UC Berkeley.

Industrial design lead at .lumen, responsible for the design of assistive glasses and prototypes. The company’s MEDICA 2025 presentation credits his design work with a Red Dot Luminary award.

Senior software tester at .lumen as reported in the company’s MEDICA 2025 presentation. Has extensive software testing experience and medical software testing certification under IEC 62304. Current employment is not independently confirmed by the current first-name-only team page.

Software lead at .lumen, working on software for AI-powered assistive glasses and pedestrian navigation. The company’s MEDICA 2025 presentation identifies him as a Romanian ISEF finalist and Forbes Under 30 honoree.

Clinical researcher at .lumen, contributing to research on usability of AI-based navigation for blind people. Her background includes academic work in public health, including at US universities, as described in the company’s MEDICA 2025 presentation.

Head of Business Development at .lumen as reported in its MEDICA 2025 presentation. The company credits him with helping write its successful EIC business plan. His continued role is not separately confirmed by the current first-name-only team page.

Clinical researcher at .lumen, also described as Testing Manager in the company’s MEDICA 2025 presentation. Works on usability and validation of assistive navigation devices for visually impaired users.

Navigation lead at .lumen, working on the AI-powered pedestrian navigation stack for assistive glasses. The company’s MEDICA 2025 presentation describes research institute experience and scientific publications.

Hardware lead at .lumen. Her background includes robotics work in Germany, and the company selected her for the EIC Women Leadership Programme in 2023. Works on the electronics and hardware for AI-powered assistive navigation glasses.

Founder and CEO of .lumen, which he established to improve independence for visually impaired people, inspired by disability in his family. Formerly Head of Innovation at Continental. Leads development of AI-powered glasses and Pedestrian Autonomous Driving technology.

Marc-Olivier Turgeon serves as Board Director at Progentos Therapeutics, a biotechnology company developing regenerative neuroscience medicines.

Andrew Miller serves as Board Chair at Progentos Therapeutics, a biotechnology company developing regenerative neuroscience medicines. Alto director appointed in May 2026. Founded Karuna Therapeutics and helped invent its schizophrenia treatment KarXT, now COBENFY, before its acquisition by Bristol Myers Squibb. He chairs Progentos and serves on Montara’s board, and holds chemical engineering degrees from MIT and Illinois.

Dan Janney serves as Board Director at Progentos Therapeutics, a biotechnology company developing regenerative neuroscience medicines.

Dmitrij Hristodorov serves as Board Director at Progentos Therapeutics, a biotechnology company developing regenerative neuroscience medicines.

Cassidy Blundell serves as Board Director at Progentos Therapeutics, a biotechnology company developing regenerative neuroscience medicines.

Paul Frohna serves as Chief Medical Officer at Progentos Therapeutics, a biotechnology company developing regenerative neuroscience medicines.

Sanjay Magavi serves as Co-Founder and Chief Scientific Officer at Progentos Therapeutics, a biotechnology company developing regenerative neuroscience medicines.

Chris Loose serves as Co-Founder and Chief Executive Officer at Progentos Therapeutics, a biotechnology company developing regenerative neuroscience medicines.

Stephen Brannan serves as Board Director at Engrail Therapeutics, a precision neuroscience drug-development company. Stephen Brannan MD is a published external PureTech collaborator, described as a neuroscience drug-development expert and former chief medical officer of Karuna Therapeutics. His existing Engrail board identity and portrait are preserved. No PureTech employment or personal investment is inferred.

Neuroscience investor and F-Prime venture partner serving on the boards of Engrail Therapeutics and Stellaromics. Joined Stellaromics’ board in February2026; works with neuroscience companies translating academic research toward clinical programs.

Saira Ramasastry serves as Board Director at Engrail Therapeutics, a precision neuroscience drug-development company.

Niall O’Donnell serves as Board Director at Engrail Therapeutics, a precision neuroscience drug-development company.

Neuroscience biotechnology entrepreneur serving on MapLight’s public advisory roster and Engrail’s board. Former Genentech neuroscience leader and co-founder of Alkahest, Circuit Therapeutics and other companies. Trained at Eötvös University, Tulane and UCSF; holds a Stanford psychiatry affiliation.

Heath Lukatch serves as Board Director at Engrail Therapeutics, a precision neuroscience drug-development company.

Jasper Bos serves as Board Director at Engrail Therapeutics, a precision neuroscience drug-development company.

Tiba Aynechi serves as Board Director at Engrail Therapeutics, a precision neuroscience drug-development company.

Peter Bisgaard is managing director of Pivotal Life Sciences and managing partner of Pivotal bioVenture Partners in the US. He joined Pivotal in 2017 after senior investment roles at Novo Ventures and earlier work at McKinsey. He holds an engineering degree from the Technical University of Denmark and chairs Engrail Therapeutics.

Rex E. Bosen serves as Senior Vice President, Finance at Engrail Therapeutics, a precision neuroscience drug-development company.

Camilla Gomiero serves as Vice President, Commercial Strategy and Business Development at Engrail Therapeutics, a precision neuroscience drug-development company.

Estibaliz Arce serves as Vice President, Translational Science and Clinical Development at Engrail Therapeutics, a precision neuroscience drug-development company.

Eve Taylor serves as Executive Vice President, Clinical Program Management and Regulatory Affairs at Engrail Therapeutics, a precision neuroscience drug-development company.

Quentin McCubbin serves as Chief Technical Officer at Engrail Therapeutics, a precision neuroscience drug-development company.

Paul Cayer serves as Chief Financial Officer at Engrail Therapeutics, a precision neuroscience drug-development company.

Kimberly Vanover serves as Chief Scientific Officer at Engrail Therapeutics, a precision neuroscience drug-development company.

Kai Wucherpfennig serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

K. Dane Wittrup serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Christophe Weber serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor. Christophe P. Weber is a Boston Scientific board director, appointed inFebruary2026. He previously served as Takeda’s chief executive and president after a long career at GlaxoSmithKline. He holds a pharmacy doctorate from Université de Lyon and has accounting and finance training. This is the same healthcare executive published by Longwood Fund as Christophe Weber.

Nobel laureate and MIT biologist studying gene expression and RNA splicing. Chairs Dewpoint's scientific advisory board and serves on Longwood Fund's strategic advisory board. Co-founded Biogen and Alnylam Pharmaceuticals.

Paul Schimmel serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Al Sandrock serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor. He is also a director of Transition Bio and President and CEO of Voyager Therapeutics.

Stefan Oelrich serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Fiona Marshall serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Lou Lange serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor. Louis “Lou” Lange is a managing member of Asset Management Ventures, LLC, confirmed in its March 2026 SEC filing. The firm’s own team directory brands him as Lou Lange, Partner. NewAmsterdam Pharma’s 2025 annual report published in2026 identifies him as an AMV general partner, physician and founder of CV Therapeutics. His Longwood Fund advisory role is retained.

Sally Kornbluth serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Anne Klibanski serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

William Hait serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Laurie Glimcher serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Stephen Elledge serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Victor Dzau serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Deborah Dunsire serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Jay Bradner serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Lotte Bjerre Knudsen serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Julie Mullen serves as Operations Manager at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Melissa Magner serves as Executive Assistant at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Christina Stephens serves as Executive Assistant at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Kevin Lewis serves as Controller at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Arielle Jackson leads corporate communications and industry engagement at Longwood Fund. She joined in 2017 and co-founded the Longwood Healthcare Leaders conference series. Her education includes a BBA from the University of Massachusetts Amherst. She is distinct from the Stanford-educated First Round marketer of the same name.

Roger Tung serves as Venture Partner at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Aparaajita Balaji serves as Associate at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Sean O’Connor serves as Principal at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Rob Hadfield serves as General Counsel and Operating Partner at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Josh Lubov serves as Chief Financial Officer at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Vikas Goyal serves as Partner at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Aleks Radovic-Moreno serves as Partner at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Neuroscience biotechnology executive serving on Goldman Sachs’ life sciences advisory board.

Biotechnology executive serving on Goldman Sachs’ life sciences advisory board.

Biotechnology executive serving on Goldman Sachs’ life sciences advisory board.

Physician-scientist advising Goldman Sachs’ life sciences team, with expertise in endocrinology and obesity research.

Harvard immunologist and TRexBio scientific founder researching T-cell differentiation, autoimmunity and inflammation. Also serves as a life sciences adviser at Goldman Sachs Alternatives.

Physician-scientist and academic leader who advises Goldman Sachs’ life sciences investment team; research expertise includes balance and inner-ear disorders. Lloyd Minor is published by aMoon as External Adviser. Stanford medical-school dean and physician-scientist whose work includes preventive and personalized medicine. This is an advisory or venture-partner affiliation; no employment or personal investment is inferred.

Goldman Sachs life sciences investor with a background in stem-cell biology and biotechnology venture investing; previously worked at insitro and The Column Group.

Goldman Sachs life sciences investor with biotechnology operations and venture-investing experience; previously worked at Qiming Venture Partners USA.

Life sciences investor at Goldman Sachs, previously a biotechnology investor at Longitude Capital and HealthCor.

Leads Goldman Sachs’ life sciences investment strategy, combining biotechnology finance and corporate transaction experience.

Michael Liebowitz serves as Clinical Advisory Board Member at Newleos Therapeutics, a clinical-stage neuroscience company.

Sanjay Mathew serves as Clinical Advisory Board Member at Newleos Therapeutics, a clinical-stage neuroscience company.

Juliane Hellhammer serves as Clinical Advisory Board Member at Newleos Therapeutics, a clinical-stage neuroscience company.

Gerard Sanacora serves as Scientific Advisory Board Member at Newleos Therapeutics, a clinical-stage neuroscience company.

Murray Stein serves as Clinical Advisory Board Member at Newleos Therapeutics, a clinical-stage neuroscience company. Murray Stein MD MPH FRCPC is a published external PureTech collaborator and distinguished professor of psychiatry and public health at UC San Diego. His existing Newleos clinical advisory identity and portrait are preserved. This is an external academic affiliation.

Raymond Camahort serves as Board Director at Newleos Therapeutics, a clinical-stage neuroscience company. Raymond Camahort, Ph.D., is Partner at Novo Holdings Venture Investments. He has over 15 years of combined investment, business, and research experience, with expertise in biochemistry, genetics, and gene therapy/editing. Prior to joining Novo Ventures, Ray worked in business development at the Harvard University Office of Technology Development where his role was to help facilitate commercialization of technologies developed in the chemistry and stem cell/regenerative biology departments. Ray has served on the Board of Directors of numerous companies, including Ray Therapeutics, Arcellx, Inspirna, iECURE, Riva Therapeutics, and OnCusp Therapeutics. He completed a National Institute of Health post-doctoral training fellowship at Harvard University and was a pre-doctoral fellow at the Stowers Institute for Medical Research in Kansas City, Missouri. He holds a Ph.D. from the University of Kansas in biochemistry and molecular biology and a B.S. in biological sciences from the University of California Santa Barbara.

Ming Cheah serves as Board Director at Newleos Therapeutics, a clinical-stage neuroscience company.

Christoph Westphal serves as Co-founder and Board Director at Newleos Therapeutics, a clinical-stage neuroscience company.

Biotechnology executive and chairman of Newleos Therapeutics, also serving on Neurogene's board. Previously chief executive officer at 89bio from June 2018 to January 2026, with earlier leadership at Avanir, Medivation and Johnson & Johnson. Holds a Dartmouth MBA and Mumbai commerce and law degrees.

Tiffany Lago serves as Vice President, Clinical Development at Newleos Therapeutics, a clinical-stage neuroscience company.

Seth Hopkins serves as Vice President, Clinical Translational Medicine at Newleos Therapeutics, a clinical-stage neuroscience company.

Marcelo Gutiérrez serves as Vice President, Clinical Pharmacology at Newleos Therapeutics, a clinical-stage neuroscience company.

Kyle Audi serves as Vice President, Finance at Newleos Therapeutics, a clinical-stage neuroscience company.

Jennifer Gervasi serves as Vice President, Program Management at Newleos Therapeutics, a clinical-stage neuroscience company.

Hector Guzman serves as Vice President, CMC and Technical Operations at Newleos Therapeutics, a clinical-stage neuroscience company.

Chris Jepsen serves as Vice President, Quality at Newleos Therapeutics, a clinical-stage neuroscience company.

Brian Shea serves as Vice President, Head of Legal at Newleos Therapeutics, a clinical-stage neuroscience company.

Adam Simmons serves as Vice President, Clinical Operations & Development at Newleos Therapeutics, a clinical-stage neuroscience company.

Lea Hachigian serves as Senior Vice President, Corporate Strategy and Operations at Newleos Therapeutics, a clinical-stage neuroscience company.

Sondra Smyrnios serves as Senior Vice President, Clinical and Technical Operations at Newleos Therapeutics, a clinical-stage neuroscience company.

John McCabe serves as Chief Financial Officer at Newleos Therapeutics, a clinical-stage neuroscience company.

Federico Bolognani serves as Co-founder, Chief Medical Officer at Newleos Therapeutics, a clinical-stage neuroscience company.

Timothy Noyes serves as Chief Executive Officer at Newleos Therapeutics, a clinical-stage neuroscience company.

Arkin director of finance, responsible for financial reporting and investor communications.

Arkin assistant controller, supporting financial statements and tax-compliance reporting.

Arkin tax director, responsible for tax planning, compliance and investment-related taxation.

Managing partner responsible for Arkin’s real-estate investment platform and international property portfolio.

Managing partner of A², the successor brand to Arkin Digital Health, overseeing digital-health investment and portfolio support.

Arkin operations and maintenance manager, providing technical and practical support to the organization.

Arkin bookkeeper and payroll accountant, supporting financial records, employee payments and tax reporting.

Arkin executive assistant and office manager, coordinating executive schedules, travel, meetings and corporate events.

Arkin Bio investment analyst with doctoral training in neuroscience, conducting scientific and financial diligence; joined in 2024.

Principal in Arkin’s real-estate business, responsible for investment analysis, acquisitions and portfolio management.

Boston-based partner at Arkin Bio, joining in 2026 after biotechnology investment roles at Leaps by Bayer and RA Capital.

Arkin bookkeeper handling supplier accounts, reconciliation and administration of charitable donations.

Principal within Arkin Equity, working on hedge-fund strategy and private-equity transactions.

Arkin legal counsel, advising on corporate transactions, financing and commercial agreements; joined in 2018.

Arkin bookkeeper supporting cash management, trading records and financial reporting; joined in 2010.

Arkin Equity investment professional focused on private and direct equity transactions, including company analysis and underwriting.

Arkin investment analyst with pharmaceutical-sciences training, focused on biotechnology diligence; joined in 2025 after working at Sphera.

Principal at Arkin Bio Ventures and member of the third early-stage fund’s management team. Trained in neural computation and previously invested at aMoon.

Principal at Arkin Bio Ventures and member of the third early-stage fund’s management team. Biotechnology scientist with corporate-development and licensing experience.

Managing partner leading Arkin Equity’s hedge-fund, private-equity and company-building activities.

CFO of Arkin Capital, overseeing finance, taxation, fund operations and corporate systems; joined in 2015.

Arkin Capital director responsible for international securities and external fund-manager allocations; also participates in technology investment decisions.

Founder and chairman of Arkin Capital. Built pharmaceutical company Agis before its sale to Perrigo, then established the investment group in 2009.

CEO of Arkin Capital, responsible for developing the group’s investment platforms and institutional relationships; joined in 2014.

Advisory Board Member at Plaisance Capital Management and molecular biologist known for research into RNA-binding proteins, alternative splicing and regulation of gene expression.

Advisory Board Member at Plaisance Capital Management and chemist whose research focuses on RNA modifications and gene regulation.

Scientific adviser to Plaisance Capital Management and bioinformatician with research experience in epigenetics, RNA biology and genomic technologies.

Stellaromics co-founder and chief scientific officer. Previously a Plaisance Capital Management principal; RNA-modification researcher and biotechnology company builder. His current scientific role supersedes the CTO title in the2023announcement.

Venture Partner and co-founder of Plaisance Capital Management, with experience in biotechnology investing and entrepreneurship. Previously co-founded Coalescence Partners; also called Frederic or Frederick Jiang.

Venture Partner at Plaisance Capital Management and technology entrepreneur associated with Everex and eMachines. Team page calls him Lap Chun (John) Hui; biography also uses Lap Shun Hui.

Office Manager at Plaisance Capital Management, with experience in international business, investor relations and Chinese-English translation.

Principal and Director of Operations at Plaisance Capital Management. Chemist with research experience in cancer therapeutics and epigenomic biomarkers; joined the firm in 2023.

Investment Associate at Plaisance Capital Management, with oncology laboratory experience and a University of Chicago degree in English and clinical research.

Principal at Plaisance Capital Management with drug discovery and business development experience. Previously worked at WuXi AppTec; trained in regenerative medicine and nerve repair.

Corporate Counsel at Plaisance Capital Management; the individual biography also calls him General Counsel. Provides legal oversight for due diligence, transactions and portfolio management; Brooklyn Law School JD.

Principal at Plaisance Capital Management, working on investment strategy, due diligence, financial modelling, deal execution and portfolio support. Also named Yunxi Li; joined in September 2023.